alpelisib

Documents about alpelisib

• Pharmacokinetic Study of Alpelisib in Subjects With Hepatic Impairment.#1150794ClinicalTrials.gov
• Investigate Bioequivalence of Alpelisib Granule and Film-coated Tablet Formulation and the Food Effect of Alpelisib Granule Formulation in Adult Healthy Volunteers#1486773ClinicalTrials.gov
• Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum#838331ClinicalTrials.gov
• Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)#1074241ClinicalTrials.gov
• A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer#1396976ClinicalTrials.gov
• 24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAs#1437194ClinicalTrials.gov
• Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)#1244361ClinicalTrials.gov
• Assessment of the Efficacy and Safety of Alpelisib (BYL719) in Pediatric and Adult Patients With Megalencephaly-CApillary Malformation Polymicrogyria Syndrome (MCAP)#1376122ClinicalTrials.gov
• Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer#1364210ClinicalTrials.gov
• Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer#991811ClinicalTrials.gov
• Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.#1419682ClinicalTrials.gov
• Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)#857480ClinicalTrials.gov
• Effect of Alpelisib in Healthy Volunteers#1086909ClinicalTrials.gov
• Continuous Glucose Monitoring Profile Description Under Alpelisib treAtment in Patients With Advanced bREast Cancer#261418ClinicalTrials.gov
• Alpelisib and Capecitabine in Patients With PIK3CA Mutant mCRC Patients#1171500ClinicalTrials.gov
• Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.#872927ClinicalTrials.gov
• Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.#1162785ClinicalTrials.gov
• Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.#836307ClinicalTrials.gov
• A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting#1009753ClinicalTrials.gov
• A Real-world Study of Effectiveness and Safety in HR+/HER2- Breast Cancer Patients Treated With Ribociclib or Alpelisib#1484515ClinicalTrials.gov
• EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+) Metastatic Breast Cancer (MBC)#1103943ClinicalTrials.gov
• Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)#1185756ClinicalTrials.gov
• Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies#1112267ClinicalTrials.gov
• Health-related Quality of Life, Symptom Severity, and Pain Among Patients With PIK3CA-related Overgrowth Spectrum: A Mixed-methods Observational Study#1307011ClinicalTrials.gov
• Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer#1281336ClinicalTrials.gov
• Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)#261467ClinicalTrials.gov
• A Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone in Patients Treated With Alpelisib for Metastatic Breast Cancer.#828230ClinicalTrials.gov
• Managed Access Program to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast Cancer#1185962ClinicalTrials.gov
• Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women#879108ClinicalTrials.gov
• Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer#1100857ClinicalTrials.gov
• A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+/HER2- Advanced BC Initiating Treatment With Risarg®, Piqray®, Endocrine Therapy or Chemotherapy in Routine Clinical Practice in Russia#1430856ClinicalTrials.gov
• Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma#847958ClinicalTrials.gov
• Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer#893620ClinicalTrials.gov
• Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations#1396502ClinicalTrials.gov